Close Menu

VEGF

Several genomic markers were associated with improved progression-free survival among patients treated with Tecentriq and Avastin versus Tecentriq alone. 

Progression-free survival times were comparable for EGFR-mutated non-small cell lung cancer cases treated with a combination of erlotinib and bevacizumab treatment or erlotinib.